[1] TSOCHATZIS EA,SENZOLO M,GERMANI G,et al. Systematic review:Portal vein thrombosis in cirrhosis[J]. Aliment Pharmacol Ther,2010,31(3):366-374.
|
[2] RIBEIRO OD,CANEDO NHS,PANNAIN VL. Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis:Correlation with pathological features[J]. Clinics(Sao Paulo),2016,71(11):639-643.
|
[3] KIM HO,KIM SK,SON BH,et al. Intraoperative radiofrequency ablation with or without tumorectomy for hepatocellular carcinoma in locations difficult for a percutaneous approach[J].Hepatobiliary Pancreat Dis Int,2009,8(6):591-596.
|
[4] Chinese Society of Hepatology,Chinese Medical Association.Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol,2019,35(11):2408-2425.(in Chinese)中华医学会肝病学分会.肝硬化诊治指南[J].临床肝胆病杂志,2019,35(11):2408-2425.
|
[5] TRIPODI A. Hemostasis in acute and chronic liver disease[J]. Semin Liver Dis,2017,37(1):28-32.
|
[6] RATNASARI N,NURDJANAH S,SADEWA AH,et al. Difference of polymorphism VEGF-gene rs699947 in Indonesian chronic liver disease population[J]. PLo S One,2017,12(8):e0183503.
|
[7] GADELHAK NA,GADELHAK SA,EL-MORSI DA,et al.Prognostic significance of three hepatitis markers(p53 antibodies,vascular endothelial growth factors and alpha fetoprotein)in patients with hepatocellular carcinoma[J]. Hepatogastroenterology,2009,56(94-95):1417-1424.
|
[8] CHO HC,KIM JH,CHA RR,et al. Clinical significance of endothelial progenitor cells in patients with liver cirrhosis with or without hepatocellular carcinoma[J]. Eur J Gastroenterol Hepatol,2020,32(1):87-94.
|
[9] ZELLER M,KORANDJI C,GUILLAND JC,et al. Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction[J]. Arterioscler Thromb Vasc Biol,2008,28(5):954-960.
|
[10] KIM TY,LEE JG,SOHN JH,et al. Hepatic venous pressure gradient predicts long-term mortality in patients with decompensated cirrhosis[J]. Yonsei Med J,2016,57(1):138-145.
|
[11] SIEGHART W,FELLNER S,REIBERGER T,et al. Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma[J]. Dig Liver Dis,2009,41(12):902-906.
|
[12] LI CP,LEE FY,HWANG SJ,et al. Spider angiomas in patients with liver cirrhosis:Role of vascular endothelial growth factor and basic fibroblast growth factor[J]. World J Gastroenterol,2003,9(12):2832-2835.
|
[13] SAMOTO K,IKEZAKI K,ONO M,et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors[J]. Cancer Res,1995,55(5):1189-1193.
|
[14] DINKOVA-KOSTOVA AT,HOLTZCLAW WD,COLE RN,et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants[J]. Proc Natl Acad Sci U S A,2002,99(18):11908-11913.
|
[15] FERRARA N,GERBER HP,LECOUTER J. The biology of VEGF and its receptors[J]. Nat Med,2003,9(6):669-676.
|
[16] GELFAND MV,HAGAN N,TATA A,et al. Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding[J]. Elife,2014,3:e03720.
|
[17] SHWEIKI D,ITIN A,SOFFER D,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis[J]. Nature,1992,359(6398):843-845.
|
[18] HOEBEN A,LANDUYT B,HIGHLEY MS,et al. Vascular endothelial growth factor and angiogenesis[J]. Pharmacol Rev,2004,56(4):549-580.
|
[19] TOSON EA,SHIHA GE,ABDELGALEEL AE. Fibrogenic/angiogenic linker for non-invasive assessment of hepatic fibrosis staging in chronic hepatitis C among egyptian patients[J].Ann Hepatol,2017,16(6):862-873.
|
[20] LI L. Risk factors of portal vein thrombosis in cirrhotic patients from the view of Virchow’s triad[J]. J Prac Hepatol,2015,18(3):325-328.(in Chinese)李玲.从Virchow三要素分析肝硬化患者发生门静脉血栓危险因素[J].实用肝脏病杂志,2015,18(3):325-328.
|
[21] Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin:Pulmonary Embolism Prevention(PEP)trial[J]. Lancet,2000,355(9212):1295-1302.
|
[22] BASILI S,RAPARELLI V,VIOLI F. The coagulopathy of chronic liver disease[J]. N Engl J Med,2011,365(2):147-156.
|
[23] ZOCCO MA,di STASIO E,de CRISTOFARO R,et al. Thrombotic risk factors in patients with liver cirrhosis:Correlation with MELD scoring system and portal vein thrombosis development[J]. J Hepatol,2009,51(4):682-689.
|
[24] FEYS HB,CANCIANI MT,PEYVANDI F,et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis[J]. Br J Haematol,2007,138(4):534-540.
|
[25] NASIM M,MAJID B,TAHIR F,et al. Cavernous transformation of portal vein in the setting of protein C and anti-thrombin III deficiency[J]. Cureus,2019,11(9):e5779.
|